Eritrea vs Syrian Arab Republic: Average cost of multi drug-resistant tuberculosis treatment
Eritrea
793 constant 2022 US$
in 2024
Syrian Arab Republic
785 constant 2022 US$
in 2024
Eritrea rank
62nd
Syrian Arab Republic rank
63rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Eritrea
- Syrian Arab Republic
How they compare
Eritrea currently reports 793 constant 2022 US$ against 785 constant 2022 US$ in Syrian Arab Republic, a difference of 8 constant 2022 US$.
The two have swapped places 2 times across 7 shared years of data; in 2018 it was Eritrea ahead.
Eritrea ranks 62nd and Syrian Arab Republic ranks 63rd of 92 countries.
Syrian Arab Republic has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eritrea | Syrian Arab Republic | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,666 constant 2022 US$ | 3,000 constant 2022 US$ | 334.5 constant 2022 US$ | Syrian Arab Republic |
| 2020s | 3,106 constant 2022 US$ | 4,182 constant 2022 US$ | 1,076 constant 2022 US$ | Syrian Arab Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Eritrea or Syrian Arab Republic?
- Eritrea, at 793 constant 2022 US$ against 785 constant 2022 US$ in Syrian Arab Republic as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Eritrea and Syrian Arab Republic?
- 8 constant 2022 US$, with Eritrea ahead.
- How many years of comparable data are there for Eritrea and Syrian Arab Republic?
- 7 years are reported by both, from 2018 to 2024.
- How do Eritrea and Syrian Arab Republic rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Eritrea ranks 62nd and Syrian Arab Republic ranks 63rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.